Apogee Therapeutics (APGE) Treasury Shares (2022 - 2026)
Apogee Therapeutics (APGE) posted quarterly Treasury Shares of $441330.0 for Q1 2026, down 63.87% year-over-year from $1.2 million in Q1 2025, and down 30.78% quarter-over-quarter from $637594.0 in Q4 2025.
Apogee Therapeutics (APGE) Treasury Shares (2022 - 2026) Analysis & Trends
Apogee Therapeutics (APGE) has reported Treasury Shares for 5 consecutive years, with $441330.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Treasury Shares fell 63.87% year-over-year to $441330.0; the TTM figure through Mar 2026 stood at $441330.0 (down 63.87% YoY), while the FY2025 annual figure was $637594.0, down 54.97% from the prior year.
- Treasury Shares fell to $441330.0 in Q1 2026 per APGE's latest filing, from $637594.0 in the prior quarter.
- Across five years, Treasury Shares topped out at $65.1 million in Q4 2022 and bottomed at $144090.0 in Q4 2023.
- Historically, Treasury Shares has averaged $17.9 million across 5 years, with a median of $1.4 million in 2024.
- Annual changes were most pronounced in 2023 — Treasury Shares tumbled 99.78% — and 2025, when it jumped 138.3%.
- Apogee Therapeutics' Treasury Shares stood at $65.1 million in 2022, then sank by 99.78% to $144090.0 in 2023, then jumped by 85.69% to $267564.0 in 2024, then surged by 138.3% to $637594.0 in 2025, then tumbled by 30.78% to $441330.0 in 2026.
- Business Quant data shows APGE's Treasury Shares at $441330.0 in Q1 2026, $637594.0 in Q4 2025, and $831989.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.08 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 92,219.00 |
| 10 | Apogee Therapeutics | 10.14 Bn | 9.16 Bn | - | 321,499.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 321,499.00 |
| Jun 30, 2026 | 321,499.00 |
| Mar 31, 2026 | 441,330.00 |
| Mar 31, 2026 | 441,330.00 |
| Dec 31, 2025 | 637,594.00 |
| Dec 31, 2025 | 637,594.00 |
| Sep 30, 2025 | 831,989.00 |
| Sep 30, 2025 | 831,989.00 |
| Jun 30, 2025 | 1.03 Mn |
| Jun 30, 2025 | 1.03 Mn |
| Mar 31, 2025 | 1.22 Mn |
| Mar 31, 2025 | 1.22 Mn |
| Dec 31, 2024 | 267,564.00 |
| Dec 31, 2024 | 267,564.00 |
| Sep 30, 2024 | 1.61 Mn |
| Sep 30, 2024 | 1.61 Mn |
| Jun 30, 2024 | 1.80 Mn |
| Jun 30, 2024 | 1.80 Mn |
| Mar 31, 2024 | 2.09 Mn |
| Mar 31, 2024 | 2.09 Mn |